What is B. Riley’s Estimate for MacroGenics FY2024 Earnings?

MacroGenics, Inc. (NASDAQ:MGNX) – Research analysts at B. Riley issued their FY2024 EPS estimates for shares of MacroGenics in a research note issued to investors on Wednesday, November 6th. B. Riley analyst M. Mamtani anticipates that the biopharmaceutical company will post earnings per share of $0.00 for the year. B. Riley has a “Neutral” rating and a $5.00 price objective on the stock. The consensus estimate for MacroGenics’ current full-year earnings is ($0.85) per share. B. Riley also issued estimates for MacroGenics’ Q4 2024 earnings at $0.82 EPS, Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at $0.57 EPS, FY2025 earnings at ($0.45) EPS, FY2026 earnings at ($1.36) EPS, FY2027 earnings at ($2.01) EPS and FY2028 earnings at ($1.54) EPS.

A number of other brokerages also recently issued reports on MGNX. JMP Securities downgraded shares of MacroGenics from an “outperform” rating to a “market perform” rating in a report on Thursday, November 7th. Evercore ISI raised shares of MacroGenics to a “strong-buy” rating in a report on Monday, September 16th. BTIG Research downgraded shares of MacroGenics from a “buy” rating to a “neutral” rating in a report on Thursday, August 1st. StockNews.com raised shares of MacroGenics from a “sell” rating to a “buy” rating in a report on Sunday. Finally, HC Wainwright reissued a “neutral” rating and issued a $4.00 price objective on shares of MacroGenics in a report on Wednesday, November 6th. Eight research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $7.63.

MacroGenics Stock Performance

NASDAQ:MGNX opened at $4.10 on Monday. The firm has a market cap of $257.33 million, a P/E ratio of -2.59 and a beta of 2.08. MacroGenics has a fifty-two week low of $2.95 and a fifty-two week high of $21.88. The firm has a 50-day simple moving average of $3.64 and a two-hundred day simple moving average of $4.74.

Hedge Funds Weigh In On MacroGenics

Large investors have recently added to or reduced their stakes in the company. EntryPoint Capital LLC purchased a new position in MacroGenics during the first quarter valued at approximately $40,000. China Universal Asset Management Co. Ltd. lifted its holdings in MacroGenics by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,064 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 4,707 shares in the last quarter. CANADA LIFE ASSURANCE Co purchased a new position in MacroGenics during the first quarter valued at approximately $52,000. SG Americas Securities LLC purchased a new position in MacroGenics during the third quarter valued at approximately $55,000. Finally, DRW Securities LLC bought a new stake in shares of MacroGenics during the second quarter valued at approximately $56,000. Hedge funds and other institutional investors own 96.89% of the company’s stock.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.